Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14672758 | 0.88 | TRPM8 (0.53) | TRPM8KDM4EMEN1HPGDKMT2A | |
| SCHEMBL71560 | 0.84 | TRPM8 (0.48) | TRPM8KDM4EMEN1HPGDKMT2A | |
| SCHEMBL14174771 | 0.79 | TRPM8 (0.49) | TRPM8KDM4EMEN1HPGDKMT2A | |
| SCHEMBL2444866 | 0.78 | MEP1B (0.49) | KMT2A | |
| SCHEMBL31550 | 0.78 | ALDH1A1 (0.51) | HPGDALDH1A1CNR2POLBAGTR1 | |
| SCHEMBL17083311 | 0.75 | PYCR1 (0.50) | MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL6433208 | 0.74 | ALDH1A1 (0.64) | TRPM8MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL3213534 | 0.74 | ALDH1A1 (0.55) | TRPM8ALDH1A1LMNAPOLB | |
| SCHEMBL16330550 | 0.73 | ALDH1A1 (0.54) | TRPM8KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL6444629 | 0.73 | FFAR3 (0.47) | KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809338-B2 | 1,2,3-triazole-based peptidomimetic integrin inhibitors for the diagnosis and therapy of tumors | UNIVERSITA' DEGLI STUDI DI FIRENZE (IT) | 2014-08-19 | — | — | US | disclosed |
| US-20130040964-A1 | 1,2,3-TRIAZOLE-BASED PEPTIDOMIMETIC INTEGRIN INHIBITORS FOR THE DIAGNOSIS AND THERAPY OF TUMORS | UNIVERSITA' DEGLI STUDI DI FIRENZE (IT) | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040964-A1 | 1,2,3-TRIAZOLE-BASED PEPTIDOMIMETIC INTEGRIN INHIBITORS FOR THE DIAGNOSIS AND THERAPY OF TUMORS | ICAM1, ITGB3, VCAM1 | TRPM8 4524/4885KDM4E 3844/4885MEN1 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.